INTRODUCTION AND OBJECTIVES: Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a newly defined subset of RCC which is characterized by various translocations involving chromosome Xp11.2. All the Xp11.2 translocations produce chimeric TFE3 genes, which retain the coding sequences for the basic helix-loop-helix leucine zipper structure (bHLH-Zip) through which TFE3 binds to DNA. It is suggested that the TFE3 fusion proteins encoded by the chimeric TFE3 genes work as constitutively active transcription factors resulting in Xp11.2 tRCC development. We aim to clarify the cancer-causing molecular mechanism of Xp11.2 tRCC by analyzing the transcriptional function of the chimeric TFE3 proteins.
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METHODS: 1) We performed comprehensive gene expression analysis by RNA sequencing (RNA-seq) to identify the gene clusters whose expressions were changed predominantly by chimeric TFE3 proteins using cell lines that expressed chimeric TFE3 proteins (PRCC-TFE3, PSF-TFE3, NONO-TFE 3) in a doxycycline-dependent manner or wild-type TFE3. 2) We performed chromatin immunoprecipitation sequencing (Chip-seq) and mapped chimeric TFE3 and wild type TFE3 binding to the genome.
RESULTS: WT-TFE3 and PRCC-TFE3 mapping on the genome revealed sharp peaks in the promoter regions, while PSF-TFE3 and NONO-TFE3 showed distinctly broader peaks. RNA-seq analysis demonstrated that PSF-TFE3 and NONO-TFE3 protein induction caused distinct gene expression changes compared to wild type TFE3 induction. In addition, gene expression changes caused by PRCC-TFE3 protein induction were also different compared to wild type TFE3 protein induction, despite the fact that mapping patterns in promoter regions were similar in both cases.
CONCLUSIONS: Our key new finding is that PSF-TFE3 and NONO-TFE3 fusions show clearly different binding patterns to the genome, and these chimeric TFE3 proteins cause distinct gene expression changes compared to wild-type TFE3. These findings suggest that chimeric TFE3 proteins contribute to carcinogenesis of renal cell carcinoma as constitutively active transcription factors that induce altered binding patterns on the genome, which result in gene expression profiles that are distinct from wild-type TFE3. 
INTRODUCTION AND OBJECTIVES:
The serine/threonine protein phosphatase-5 (PP5) plays a key role in the regulation of both hormone-and stress-induced signaling networks that allow cells to respond appropriately to genomic stress. A role for PP5 has been implicated previously in breast and colorectal cancer. The majority of PP5 substrates are in complex with the molecular chaperone heat shock protein-90 (Hsp90) and include the glucocorticoid receptor (GR), tumor suppressor p53 and the co-chaperone Cdc37. PP5 also functions as a co-chaperone of Hsp90 and its dephosphorylation of Cdc37 in complex with Hsp90 activates kinase clients. Hsp90 and its co-chaperones are subject to post-translational modifications (PTMs) that regulate their activity. The objective of this study was to determine and dissect the mechanism of Casein kinase-1 d and von Hippel-Lindau protein (VHL) mediated post-translational regulation of PP5 in cells. We hypothesized that PP5 hyperactivity plays an important role in kidney cancer.
METHODS: Site-directed mutagenesis followed by in vitro and in vivo functional assays identified a phosphorylation site that controls PP5 activity and VHL-mediated ubiquitination sites on PP5. The effect of PP5 phosphorylation on survival of clear cell renal cell carcinoma (ccRCC) cells and tumors derived from patients were analyzed by Western blot, flow cytometry, and proliferation and colony formation assays.
RESULTS: Casein kinase-1 d (CK1d) phosphorylates T362 in the catalytic domain of PP5, which activates and enhances its phosphatase activity independent of Hsp90. Our proteomic approach identified the tumor suppressor von Hippel-Lindau protein (VHL) to interact and ubiquitinate K185/K199-PP5 for proteasomal degradation in a hypoxia-and prolyl hydroxylation-independent manner. VHL-deficient ccRCC cell lines and patient tumors exhibit elevated PP5 levels relative to VHL-WT. Down-regulation of PP5 by siRNA or blocking PP5 phosphorylation by pharmacologic inhibition of CK1d causes VHL-deficient ccRCC cells to undergo apoptosis.
CONCLUSIONS: Small interfering RNA (siRNA) mediated silencing of PP5 or pharmacological inhibition of CK1d, hence killing PP5 activity causes apoptosis in VHL-deficient ccRCC cells. This indicates that PP5 plays a prosurvival role in ccRCC. Targeting PP5 may ultimately have therapeutic implications. METHODS: The expression level of miR-10b was evaluated through the meta-analysis of eligible studies reported miR-10b expression in multiple cancers and miRNA probe test in RCC tissue. The function of miR-10b and its down-stream molecular MAPKs was investigated in RCC cell lines via Transwell, MTS and EdU assays. The mechanism of SETD2-miR-10b-MAPKs was predicted by TCGA and Targetscan database. After knocking down SETD2 or miR-10b, this pathway was verified by chromatin immunoprecipitation(ChIP), luciferase assays et al. In the xenograft assay, three groups of Balb/c nude mices were treated with shSETD2, shSETD2þmimics-miR-10b and shLacZ in 786-O cell line, respectively.
RESULTS: SETD2 and miR-10b were downregulated in RCC. After up regulation of miR-10b by RNAi interference, the ability of proliferation, invasion and migration of RCC cells was Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e895
